© Reuters. Baupost Group dumps Akebia Therapeutics, Inc.
On the 30th of September, the Baupost Group sold all their 18 million Akebia Therapeutics, Inc. (NASDAQ:) shares for $44 million at an average price of $2.51 per share.
Shares of Akebia Therapeutics, Inc. are up 17.53% since the transaction.
The Baupost Group’s holding in Akebia Therapeutics, Inc. were completely closed with the transaction.
The Baupost Group first bought Akebia Therapeutics, Inc. stock in the fourth quarter of 2018.
The Baupost Group also owns Theravance Biopharma, Inc. (NASDAQ:).
Akebia Therapeutics, Inc. was its pre-sell number two position by number of shares and market value among pharmaceuticals stocks.
Other investors who also sold all their Akebia Therapeutics, Inc. shares include Millennium Management.
Contrary to the Baupost Group, California State Teachers Retirement System, the T. Rowe Price Equity Income Fund, and Victory Capital Management added to AKBA shares.
The Baupost Group also added to their share in Viasat, Inc. (VSAT) and Translate Bio, Inc. (NASDAQ:).
The total value of the shares bought is estimated at around $103 million.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.